- Home
- USIO vs ATNM Comparison
USIO vs ATNM Comparison
Compare USIO & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | USIO | ATNM |
|---|---|---|
| Founded | 1998 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.0M | 36.8M |
| IPO Year | 1999 | 2013 |
Fundamental Metrics
Financial Performance| Metric | USIO | ATNM |
|---|---|---|
| Price | $1.10 | $1.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $4.00 | $4.00 |
| AVG Volume (30 Days) | 56.7K | ★ 107.3K |
| Earning Date | 03-18-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.60 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $28,200,535.00 | $81,000.00 |
| Revenue This Year | $15.47 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.69 | N/A |
| 52 Week Low | $1.03 | $1.01 |
| 52 Week High | $2.02 | $1.95 |
Technical Indicators
Market Signals| Indicator | USIO | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 34.19 | 35.84 |
| Support Level | $1.03 | N/A |
| Resistance Level | $1.42 | $1.71 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 31.18 | 0.00 |
Price Performance
Historical ComparisonAbout USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.